Ann: Security Class Reinstatement to Quotation- OPTOB, page-554

Does anyone know what multiple does Mr. Market typically pays for a commercial drug with a long patent and captive market?

Regeneron generates $13 billion in annual drug sales and is valued at US$74B

This gives it a sales-to-market-cap ratio of 5.35.

Now, let’s assume a conservative 50% boost in sales by introducing the only combination drug on the market that offers significantly improved efficacy; "Want to drive... you need Eylea-Surevision with extra OPT-302".

Regeneron would effectively have a new blockbuster. That’s a $6.5 billion boost to annual sales.

Calculating it out:6.5×5.35= US$35.7B or AUD $55 billion.

When you break it down, that’s a staggering $42 per share. I know, it sounds a bit crazy to type $42/share and I know in reality it would be a fraction of that, but still if we hit 5 letters. $10-$20 why not? Regeneron has AUD$13 in its petty cash draw